Showing posts with label elder-care. Show all posts
Showing posts with label elder-care. Show all posts

Thursday, March 8, 2007

Exercise slows decline in Alzheimer's patients


I can attest, exercise makes a difference. My mother now has the tendency to sit around all day. On those days when I can get her to go to Gold's Gym with me she is a completely different person. The look on her face, from dull to smiling, is more than enough to tell me that exercise works to her benefit.

"Nursing home residents with Alzheimer's disease who participate in a moderate exercise program have a significantly slower deterioration than those who receive routine medical care, researchers have shown."

Read the article in its entirety at the CareGiver: The Book Weblog

Saturday, February 24, 2007

Study links seniors' loneliness to higher risk of dementia



Loneliness may put people at risk of an Alzheimer's-like dementia, a study reported Monday.
"People who described themselves as lonely were twice as likely to develop dementia," says researcher Robert Wilson of the Rush University Medical Center in Chicago.


Source USA Today

By Kathleen Fackelmann, USA TODAY

Loneliness may put people at risk of an Alzheimer's-like dementia, a study reported Monday.
"People who described themselves as lonely were twice as likely to develop dementia," says researcher Robert Wilson of the Rush University Medical Center in Chicago.

Other studies have found that people who are unmarried and socially isolated are at higher risk for dementia, including Alzheimer's. But this study is one of the first to show a link between loneliness — or the feelings of disconnection from other people — and a higher risk of developing dementia late in life, says Laurel Coleman, a spokeswoman for the Alzheimer's Association and a geriatrician in Portland, Maine.

Wilson and his colleagues studied 823 people who were about 80 years old and had no sign of dementia at the start of the study. The team gave the recruits a loneliness quiz and tested them annually for signs of memory loss and confusion, two key signs of dementia and Alzheimer's.

During the four-year study, 76 people developed an Alzheimer's-like dementia, Wilson says. The risk of developing dementia increased about 51% for each one-point increase on the loneliness scale. People with the highest scores had 2.1 times the risk of developing dementia, a group of conditions that destroy brain cells and lead to mental confusion. Alzheimer's is the most common form of dementia.

Autopsies were performed on 90 people who died during the study. The researchers found no link between loneliness and the development of the abnormal brain deposits that are the hallmark of Alzheimer's.

That finding suggests loneliness might be triggering dementia through a novel mechanism — one that doesn't lead to a brain riddled with deposits, Wilson says.

One theory is that people who are lonely over long periods of time might have higher levels of damaging stress hormones. The elevated stress hormones might lead to an accelerated aging of the brain — and perhaps to dementia, Wilson says.

Other research suggests lonely people are at risk of other health problems such as cancer and high blood pressure, says John Cacioppo of the University of Chicago. Still, he says, the new finding, which appears in February's Archives of General Psychiatry, must be verified by additional research.

The findings didn't change much when the team factored in markers of social isolation, such as infrequent participation in social events. That means that people who have a small number of good friends might be better off than those with a busy social schedule but chronic feelings of loneliness, Wilson says.

But lonely people often benefit from signing up for a new class or activity, Coleman says. Research shows that such activities might protect aging brain cells. And seniors who are out and about are more likely to make new friends, which might lessen feelings of loneliness, she says.




The CareGiver Blog
Robert T DeMarco
The Alzheimers Reading Room
AllAmerican Senior Care Weblog




Wednesday, February 21, 2007

New Drug Stops Alzheimer's In Tracks


The drug -- called Alzhemed -- attacks Amyloid Peptide - the molecule that causes Alzheimer's.

Paul Aisen, M.D.: "I think it is tremendously significant."

An early study showed Alzhemed stabilized the disease in nearly half of patients. Now, more than 1,000 are being followed.




Source ABC7


Nearly five-million Americans are living with Alzheimer's disease. Drugs on the market can treat the symptoms -- but not one goes after what causes it. Now, researchers are on the brink of a huge breakthrough with a drug that targets the cause and could stop the disease in its tracks.

Frances Goldstein: "I like to paint -- a lot."

Jacobo, her husband of 45 years, loves watching her mind at work. Frances has Alzheimer's disease -- diagnosed eight years ago at age 56.

Jacobo Goldstein, Wife has Alzheimer's: "For the first nine months, I couldn't tell her the word Alzheimer's because I was afraid, you know, that she might go into tremendous shock."

Instead, Frances fought back. For three years, she's been in a study testing a drug that could change her prognosis. Current Alzheimer's drugs target the symptoms of the disease...like memory loss and emotional problems. Well this new drug is taking a more direct approach.

Paul Aisen, M.D., Alzheimer's Specialist: "This drug is attacking the cause of Alzheimer's disease. If it works, it will change the course of the disease and that will represent a real breakthrough."

The drug -- called Alzhemed -- attacks Amyloid Peptide - the molecule that causes Alzheimer's. In mice, watch as the drug clears the molecule from the brain.

Paul Aisen, M.D.: "I think it is tremendously significant."

An early study showed Alzhemed stabilized the disease in nearly half of patients. Now, more than 1,000 are being followed.

Paul Aisen, M.D.: "If the phase three study confirms that the drug is effective, we will have a way of slowing the progression of Alzheimer's disease for the first time."

Frances takes Alzhemed twice a day.

Jacobo Goldstein: "I don't know where we would be if it wasn't for this. We have no idea. I know what she does now. If we can stay the way we are, we would be forever grateful."

With hope in hand, Frances continues to make every day and every painting count.

To date, more than 600 patients have completed one year of treatment on the medication. The study is scheduled to be complete soon. More than 70 centers across the United States and Canada are taking part. Side effects of the drug have been minimal and primarily include mild gastrointestinal symptoms.

Copyright 2007, ABC7/KGO-TV/DT.